Dr. Dall’Era specializes in the management of malignant disease of the urinary tract.
The specialty care Dr. Dall’Era offers includes:
- Multi-disciplinary and comprehensive care of patients with urologic malignancy
- Active surveillance for low risk prostate cancer
- Multi-parametric MRI/US fusion targeted prostate biopsy
- Blue Light Fluorescent cystoscopy for bladder cancer with Cysview
- Minimally invasive and robotic surgery of the kidney and prostate including prostatectomy, partial nephrectomy, pyeloplasty/ureteral reconstruction
- Radical cystectomy and neobladder creation
- Advanced genomics testing of urologic cancers
Dr. Dall'Era's research interests include active surveillance for prostate cancer including utilization of mp-MRI and biomarker discovery and validation. He is also involved in translational research for urothelial cancer diagnosis and management including advanced genomics analysis of bladder tumor.
B.S., UC Davis, Davis CA 1995
Chief Resident, University of Washington, Seattle WA 2005-2006
Society of Urologic Oncology
Western Section, American Urological Association
Select Recent Publications:
To view a detailed list of Dr. Dall'Era's publications, please click here.
Dall’Era MA, Maddala T, Polychronopoulos L, Gallagher JR, Febbo PG, Denes BS. Utility of the Oncotype DX Prostate Cancer Assay in Clinical Practice for Treatment Selection in Men Newly Diagnosed with Prostate Cancer: A retrospective Chart Review Analysis. Urology Practice. 2015;2,343-348.
Yuh L, Dall’Era MA, Penson DF, Evan CP. Active Surveillance for Prostate Cancer Under the Patient Protection and Affordable Act. Urology Practice. 2015;2(4):154-159.
Pugashetti N, Yap SA, Lara PN, Gandour-Edwards R, Dall’Era MA. Metastatic signet-ring cell carcinoma of the urinary bladder: A novel management approach to a rare tumour. Canadian Urological Association Journal. 2015;9(3-4):E204-207.
Belair CD, Paikari A, Moltzahn F, Shenoy A, Yau C, Dall’Era M, Simko J, Benz C, Blelloch R. DGCR8 is Essential for Tumor Progression following PTEN loss in the prostate. EMBO. 2015;16(9):1219-32.
Tomlinson B, Lin TY, Dall’Era M, Pan CX. Nanotechnology in Bladder Cancer: Current State of Development and Clinical Practice. Nanomedicine (Lond). 2015;10(7):1189-1201.
Wu JN, Fish KM, Evans CP, Devere White RW, Dall'Era MA. No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period. Cancer. 2014;120(6):818-23.
Dall'Era MA. The economics of active surveillance for prostate cancer. Curr Opin Urol. 2013;23(3):278-82. Review.
Dall'Era MA, Albertsen PC, Bangma C, Carroll PR, Carter HB, Cooperberg MR, Freedland SJ, Klotz LH, Parker C, Soloway MS. Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol. 2012;62(6):976-83. Review.
Keegan KA, Dall'Era MA, Durbin-Johnson B, Evans CP. Active surveillance for prostate cancer compared with immediate treatment: an economic analysis. Cancer. 2012;118(14):3512-8.
Dall'Era MA, Cooperberg MR, Chan JM, Davies BJ, Albertsen PC, Klotz LH, Warlick CA, Holmberg L, Bailey DE Jr, Wallace ME, Kantoff PW, Carroll PR. Active surveillance for early-stage prostate cancer: review of the current literature. Cancer. 2008;112(8):1650-9. Review.